Shares of Genetic Technologies Limited (NASDAQ:GENE) last traded at $0.84. (NASDAQ:GENE) performance year to date is -22.23%. The 200 day simple moving average is -36.92%. The 200 SMA is considered a major indicator by market analysts and traders for determining the long-term trend. The price in the market that coincides with the 200 day SMA is recognized as a key support when price moves above the 200 day SMA or resistance when price drops below the same.
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Genetic Technologies Limited (NASDAQ:GENE) has been in the buzz for all the right reasons.
The Barchart Technical Opinion rating is a 96% Sell with a Strongest short term outlook on maintaining the current direction. Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend. The market is approaching oversold territory. Be watchful of a trend reversal.
The Exponential Moving Average is similar to a simple moving average but it uses a weighting element that exponentially drops from the recent data point. EMA analysis assesses the short term,5 days and 13 days, intermediate term that is 20 days and long-term 50 days EMA. These EMAs will give bullish indications when moving above trailing EMAs and below the latest price and vice versa. EMA alerts comprise crossovers that is the 5 day EMA crosses below/above the 20 day EMA and EMA convergences, 5 day EMA comparable to 13 day EMA. The 5 day EMA 0.97 is higher than the last trade price suggesting a short term bearish pattern building up. Long term, the 50 day EMA 1.11 is also higher than the current trading price depicting a bearish trend overall..
The relative strength index is a momentum oscillator that can measure the magnitude of stock price and velocity changes. Momentum is computed as the ratio of plus price changes to negative price changes. The RSI assessment compares the prevailing RSI against oversold (30), overbought (70) and neutral (50) conditions. Alerts will apprise you when stocks retreat from overbought/oversold levels or breakthrough neutral (50). The current RSI is 16.01 suggesting a bearish price action.
Genetic Technologies Limited (NASDAQ:GENE) is all set to report its earnings on -. As per Zack’s analyst scores, Genetic Technologies Limited (NASDAQ:GENE) currently has a mean brokerage rating of . On a scale of 1-5, a rating of 1 or 2 would imply a buy, and a rating of 4 or 5 would indicate a sell recommendation. A rating of 3 would represent a hold on the equity. The consensus target price on (NASDAQ:GENE) is $ with a high of $ and a low of $.
As such, while we consider Genetic Technologies Limited (NASDAQ:GENE) represents a enthralling growth story open to several attractive markets, it would be fascinating to see how it works for long-term shareholders.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.